TGTX earnings date and last-quarter result: next report 2026-08-03, last quarter miss, P/E 16.57. Updated 2026-07-23.
TG Therapeutics (TGTX) Research Hub
TG Therapeutics (TGTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 54.79 USD (+1.14%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 16.57, market cap 8.12B. This hub links to the full technical, earnings and options research available for TGTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 54.79 USD (+1.14%) |
| 52-week range | 45.37 USD – 59.3 USD |
| Trend regime | Range |
| 14-day RSI | 60.2 (Bullish) |
| Trailing P/E | 16.57 |
| Market cap | 8.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for TGTX
Covered Call on TGTX: how it works, illustrative setup around the real 54.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TGTX: how it works, illustrative setup around the real 54.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TGTX: how it works, illustrative setup around the real 54.79 USD price, max profit/loss, breakeven and when to use it. Educational.
TGTX technical analysis: range, last 54.79 USD, RSI 60.2, 52w range 45.37 USD–59.3 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TGTX in?
TG Therapeutics (TGTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TGTX in an uptrend or downtrend?
As of 2026-10-26, TGTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TGTX's trailing P/E ratio?
TGTX's trailing P/E is 16.57, with a market cap of 8.12B. See the earnings research page for full valuation detail.
When does TGTX next report earnings?
TGTX is next scheduled to report earnings on 2026-08-03.